Ignite Creation Date:
2025-12-24 @ 11:07 PM
Ignite Modification Date:
2026-02-22 @ 9:05 AM
Study NCT ID:
NCT01995669
Status:
COMPLETED
Last Update Posted:
2025-06-24
First Post:
2013-11-20
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Grade 3a Follicular Lymphoma | View |
| None | Recurrent Follicular Lymphoma | View |
| None | Recurrent Grade 1 Follicular Lymphoma | View |
| None | Recurrent Grade 2 Follicular Lymphoma | View |
| None | Recurrent Grade 3 Follicular Lymphoma | View |
| None | Recurrent Marginal Zone Lymphoma | View |
| None | Recurrent Small Lymphocytic Lymphoma | View |
| None | Refractory Follicular Lymphoma | View |
| None | Refractory Marginal Zone Lymphoma | View |
| None | Refractory Small Lymphocytic Lymphoma | View |
Keywords: